Biocon Biologics secures Health Canada nod for biosimilars Yesintek, Yesintek IV

Yesintek and Yesintek I.V. are approved for the treatment of moderate to severe plaque psoriasis in adults and pediatric patients

Gujarat Themis Biosyn doubles fermentation production capacity at Vapi

With this expansion, the overall fermentation capacity of the company has increased from 450 KL to 990 KL

Biocon Biologics and Civica launch private-label Insulin glargine

BioMed X launches women’s health R&D accelerator ‘XFem labs’ in Germany

First research project, supported by the Gates Foundation, focuses on developing non-hormonal contraceptives for women in low- and middle-income countries

Biocon gets 1 USFDA observation for Cranbury site

The Cranbury facility represents a strategic advancement of the company's operations in the Unted States

Samsung Biologics introduces optimized manufacturing framework ‘ExellenS’

ExellenS applies optimized facility designs, equipment, and processes across all sites to ensure equivalency and speed

Lonza receives Swissmedic approval for Biologics drug product filling line in Stein

New filling line approval supports delivery of integrated, end-to-end solutions across the entire biologics and bioconjugates value chain

Briefs: Panacea Biotec and Shukra Pharmaceuticals

Panacea Biotec receives acceptance from CMSS for supply of bOPV

RedHill Biopharma inks $1.8 million Middle East licensing deal for Talicia

RedHill will receive $500,000 in guaranteed payments, including a $250,000 upfront payment and $250,000 in fixed payments due within 18 months

Biocon and Carnegie receive FDA tentative approval for Rifaximin tablets

Rifaximin tablets are a rifamycin antibacterial indicated for reducing the risk of overt hepatic encephalopathy